Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR)


Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR)
From other sites
Comments (1)
  • jamaicanholiday
    , contributor
    Comments (48) | Send Message
     
    Clinical Stage BioPharma............e... are irrelevant. Pipeline & Cash are most important. Great advancements on both fronts. Share price will climb. Company positioning itself for future success. Buy in dips.
    1 Mar 2013, 08:37 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs